C07C 317/48
The carbon skeleton being further substituted by singly-bound nitrogen atoms, not being
Official title: the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
C07C317/48 (The carbon skeleton being further substituted by singly-bound nitrogen atoms, not being) appears on 345 US grants and 323 published applications in this corpus.
Search patents in C07C- Granted patents
- 345
- Published applications
- 323
- Assignees
- 196
- Inventors
- 965
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 3 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 3 | 0 |
| 1992 | 4 | 0 |
| 1993 | 6 | 0 |
| 1994 | 4 | 0 |
| 1995 | 9 | 0 |
| 1996 | 14 | 0 |
| 1997 | 18 | 0 |
| 1998 | 10 | 0 |
| 1999 | 9 | 0 |
| 2000 | 7 | 0 |
| 2001 | 9 | 2 |
| 2002 | 17 | 12 |
| 2003 | 15 | 24 |
| 2004 | 9 | 20 |
| 2005 | 12 | 11 |
| 2006 | 8 | 6 |
| 2007 | 11 | 10 |
| 2008 | 8 | 6 |
| 2009 | 8 | 19 |
| 2010 | 10 | 15 |
| 2011 | 9 | 14 |
| 2012 | 9 | 14 |
| 2013 | 11 | 15 |
| 2014 | 15 | 23 |
| 2015 | 14 | 31 |
| 2016 | 14 | 17 |
| 2017 | 15 | 17 |
| 2018 | 11 | 11 |
| 2019 | 13 | 11 |
| 2020 | 4 | 9 |
| 2021 | 7 | 2 |
| 2022 | 2 | 7 |
| 2023 | 2 | 9 |
| 2024 | 7 | 7 |
| 2025 | 8 | 10 |
| 2026 | 2 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives21 Apr 2026US 12,606,522 B2OrsoBio, Inc.
- Compositions and methods for treatment24 Feb 2026US 12,558,350 B2Bausch + Lomb Ireland Limited
- Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto9 Dec 2025US 12,490,741 B2Corteva Agriscience LLC
- Phenylalanine-based LAT1 inhibitors and uses thereof30 Sep 2025US 12,427,124 B1Maxymune Therapeutics, Inc.
- WDR5-MYC inhibitors26 Aug 2025US 12,398,097 B2Vanderbilt University
- Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives16 Jul 2026US 2026/0200844 A1OrsoBio, Inc.
- Aromatic compound and use thereof25 Dec 2025US 2025/0388560 A1Hitgen Inc.
- Blue light blocking compound, blue light blocking composition, use of blue light blocking compound, use of blue light blocking composition and method for preparing blue light blocking compound18 Dec 2025US 2025/0382439 A1Visco Vision Inc.
- Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto27 Nov 2025US 2025/0359552 A1Corteva Agriscience LLC
- Phenylalanine-based lat1 inhibitors and uses thereof6 Nov 2025US 2025/0339388 A1Maxymune Therapeutics, Inc.
Most cited
By later US patents
- Compositions and methods for treatment of eye disorders84US 8,168,655 B2Sarcode Bioscience Inc. · 2012
- 5-fluoroanthranilic fungicides76US 5,093,364 ASchering Agrochemicals Limited · 1992
- N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives56US 7,176,242 B2Elan Pharmaceuticals, Inc. · 2007
- Enzyme inhibitors45US 8,686,032 B2Chroma Therapeutics Ltd. · 2014
- Amino acid derivative anticonvulsant44US 5,378,729 AResearch Corporation Technologies, Inc. · 1995